Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.

摘要: The bioactive lysophospholipid sphingosine-1-phosphate (S1P) is best known for its activity as T-cell-active chemoattractant regulating the egress of T cells from lymph node and, consequently, availability migration into peripheral tissues. This physiological role S1P exploited by drug fingolimod, a first-line therapy multiple sclerosis, which "detains" in nodes. In recent year, it has been elucidated that exerts regulatory functions far beyond T-cell node. Thus, additionally regulates, among others, homing several immune cell populations tissues under inflammatory conditions. addition, evidence, mostly derived mouse models, accumulated may be involved pathogenesis skin disorder and receptor modulators applied topically are effective treating diseases. These developments highlight pharmacological modulation S1P/S1P system potential new therapeutic strategy plethora impact on diseases next requires testing human patients.